Evidence map›Paper›PMID 12186931›Full record

ArticleJournal of virology2002

A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques.

W L William Chang, Alice F Tarantal, Shan Shan Zhou, Alexander D Borowsky, Peter A Barry

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. CD8Science advances · 2024
    Article
  3. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

W L William ChangCenter for Comparative Medicine and Department of Medical Pathology, University of California, Davis, California 95616, USA.
Alice F Tarantal
Shan Shan Zhou
Alexander D Borowsky
Peter A Barry
University of California, Davis · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10R01AI049342 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2002 to 2017
$6.9M
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CMVR01NS036859 · NINDS · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A · 1998 to 2002
$601k
Prevention of Primary HCMV Infection by Vaccinating Against HCMV-Encoded IL-10R56AI049342 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2012 to 2012
$401k
NCRR NIH HHS P51 RR000169NCRR NIH HHS RR-00169NIAID NIH HHS AI49342NIAID NIH HHS R01 AI049342NIAID NIH HHS R56 AI049342NINDS NIH HHS NS-36859
6 · The paper itself

Abstract

To facilitate identification of rhesus cytomegalovirus (RhCMV)-infected cells, a recombinant virus expressing enhanced green fluorescent protein (EGFP), designated RhCMV-EGFP, was constructed. An expression cassette for EGFP under the control of the simian virus 40 (SV40) early promoter was inserted into the intergenic region between unique short 1 (US1) and US2 of the RhCMV genome by homologous recombination. RhCMV-EGFP exhibited comparable growth kinetics to that of wild-type virus in rhesus fibroblast cultures and retained its pathogenicity in monkey fetuses. Typical neurologic syndromes caused by CMV infection were observed in all fetuses experimentally inoculated with RhCMV-EGFP, as evidenced by sonographic and gross examinations. Systemic RhCMV infections were established in all fetuses, as viral antigen was detected in multiple organs and virus was isolated from fetal blood samples. The engineered viral genome was stable following rapid serial passages in vitro and multiple rounds of replication in vivo. Infected cells could be readily distinguished by green fluorescence both in tissue cultures and in the fetuses. In addition, EGFP expression was detected in various cell types that were permissive to RhCMV infection, consistent with a broad tissue tropism of the SV40 promoter. These results demonstrate that RhCMV can be successfully engineered without loss of wild-type replication and pathogenic potential. Further, the spectrum of cortical anomalies and the distribution of infected cells in the brain tissues indicated that RhCMV may have preferentially targeted immature neuronal cells. The pattern of RhCMV infection in the central nervous system may offer an explanation for the severe developmental outcomes associated with congenital human CMV infection early in gestation.

Indexed as

Recombination, GeneticAnimalsBrainBrain DiseasesCentral Nervous System Viral DiseasesCytomegalovirusCytomegalovirus InfectionsDisease Models, AnimalFemaleFetal DiseasesGreen Fluorescent ProteinsHumansLuminescent ProteinsMacaca mulattaPhenotypePregnancyGreen Fluorescent ProteinsLuminescent Proteins

Identifiers

PMID12186931
PMCPMC136446
OpenAlexW2110611572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.